PITTSBURGH, Dec. 15, 2013 – The lung lesions in an individual infected with tuberculosis (TB) are surprisingly variable and independent of each other, despite whether the patient has clinically active or latent disease, according to a new animal study led by researchers at the University of Pittsburgh School of Medicine. The findings, published online today in Nature Medicine, could point the way to new vaccines to prevent the hard-to-treat infection.
More than 30 percent of the world's population is infected with Mycobacterium tuberculosis, the bacterium that causes TB, yet only 5 to 10 percent of those infected develop active, contagious disease with symptoms of coughing, chest pain, night sweats and weight loss. Most have asymptomatic, or "latent," infections that are not contagious, but could become active years later.
When the lungs become infected with M. tuberculosis, the body's immune system walls off the bacteria into lesions called granulomas, explained co-senior investigator JoAnne Flynn, Ph.D., professor of microbiology and molecular genetics, Pitt School of Medicine.
"It's long been thought that the patient with a weakened immune system or some other immune vulnerability was more likely to develop active disease," Dr. Flynn said. "But to our surprise, our study showed that every infected individual has a collection of granulomas, some containing live bacteria and some that are sterile because the immune system has killed all the bacteria. So in this sense, there's no such thing as a latent or active granuloma."
For the study, the research team infected monkeys with TB and then carefully tracked the granulomas that developed in the lungs. They determined that each granuloma starts with only one bacterium, and that bacterial replication continued for about four weeks before the body counters with an adaptive immune response to kill off the invaders.
"This response was sufficient to kill all the bacteria and sterilize some granulomas, but bacteria persisted in others and spread to create new granulomas," Dr. Flynn said. "You need only one granuloma to 'go bad' in order to get active TB."
Even when an animal had a severe, active infection, some of their granulomas were sterile, indicating the immune system was capable of killing bacteria, the researchers found.
"We don't know yet why the immune response produced different results in different lesions," Dr. Flynn said. "When we develop a deeper understanding of why the immune response produced different results in different lesions, we will be closer to harnessing the right mechanisms to develop effective vaccines to prevent TB."
In addition to co-senior author Sarah Fortune, M.D., of Harvard University, the research team included Philana Ling Lin, M.D., of Children's Hospital of Pittsburgh of UPMC; M. Teresa Coleman, and Amy J. Myers, of the University of Pittsburgh School of Medicine; Christopher B. Ford, Ph.D., of Harvard University and the Broad Institute; Richa Gawande, of Harvard University; and Thomas Ioerger, Ph.D., and James Sacchettini, Ph.D., of Texas A&M University.The project was funded by the Bill & Melinda Gates Foundation; the Otis Childs Trust of the Children's Hospital of Pittsburgh Foundation; National Institutes of Health (NIH) grants HL106804, AI094745, DP2 0D001378 and AI076217; the NIH's National Institute of Allergy and Infectious Diseases grant DAIT BAA-05-10, the Howard Hughes Medical Institute, the Physician Scientist Early Career Award, the Harvard Merit Fellowship, the Burroughs Wellcome Foundation Investigator in the Pathogenesis of Infectious Diseases Fellowship, the Robert A. Welch Foundation and the Melvin J. and Geraldine L. Glimcher Associate Professorship.
About the University of Pittsburgh School of Medicine
As one of the nation's leading academic centers for biomedical research, the University of Pittsburgh School of Medicine integrates advanced technology with basic science across a broad range of disciplines in a continuous quest to harness the power of new knowledge and improve the human condition. Driven mainly by the School of Medicine and its affiliates, Pitt has ranked among the top 10 recipients of funding from the National Institutes of Health since 1998. In rankings recently released by the National Science Foundation, Pitt ranked fifth among all American universities in total federal science and engineering research and development support.
Likewise, the School of Medicine is equally committed to advancing the quality and strength of its medical and graduate education programs, for which it is recognized as an innovative leader, and to training highly skilled, compassionate clinicians and creative scientists well-equipped to engage in world-class research. The School of Medicine is the academic partner of UPMC, which has collaborated with the University to raise the standard of medical excellence in Pittsburgh and to position health care as a driving force behind the region's economy. For more information about the School of Medicine, see http://www.medschool.pitt.edu.http://www.upmc.com/media